Ignite Creation Date:
2024-05-05 @ 11:34 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00082433
Status:
COMPLETED
Last Update Posted:
2020-11-02
First Post:
2004-05-07
Brief Title:
Epothilone Ixabepilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
Sponsor:
R-Pharm
Organization:
R-Pharm
Study Overview
Official Title:
A Phase III Study of Novel Epothilone Ixabepilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously Treated With an Anthracycline and a Taxane
Status:
COMPLETED
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine Xeloda provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer Patients should have previously received an anthracycline and a taxane The safety of this treatment will also be studied
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None